CO6190511A2 - 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 - Google Patents

2-fenilindoles como antagonistas del receptor de la prostaglandina d2

Info

Publication number
CO6190511A2
CO6190511A2 CO09002745A CO09002745A CO6190511A2 CO 6190511 A2 CO6190511 A2 CO 6190511A2 CO 09002745 A CO09002745 A CO 09002745A CO 09002745 A CO09002745 A CO 09002745A CO 6190511 A2 CO6190511 A2 CO 6190511A2
Authority
CO
Colombia
Prior art keywords
phenylethyl
hydrogen
chloro
dichloro
methoxy
Prior art date
Application number
CO09002745A
Other languages
English (en)
Spanish (es)
Inventor
Zhaoxia Yang
Stephan Reiling
Thaddeus R Nieduzak
Rose M Mathew
Sharon Jackson
Keith John Harris
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CO6190511A2 publication Critical patent/CO6190511A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CO09002745A 2006-07-25 2009-01-15 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 CO6190511A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82030106P 2006-07-25 2006-07-25
US82030206P 2006-07-25 2006-07-25
US82029906P 2006-07-25 2006-07-25

Publications (1)

Publication Number Publication Date
CO6190511A2 true CO6190511A2 (es) 2010-08-19

Family

ID=38610820

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09002745A CO6190511A2 (es) 2006-07-25 2009-01-15 2-fenilindoles como antagonistas del receptor de la prostaglandina d2

Country Status (25)

Country Link
US (1) US20090176804A1 (enExample)
EP (1) EP2066628B1 (enExample)
JP (1) JP2009544721A (enExample)
KR (1) KR20090039735A (enExample)
AR (1) AR062051A1 (enExample)
AT (1) ATE485270T1 (enExample)
AU (1) AU2007276885A1 (enExample)
BR (1) BRPI0714554A2 (enExample)
CA (1) CA2659055A1 (enExample)
CL (1) CL2007002163A1 (enExample)
CO (1) CO6190511A2 (enExample)
CR (1) CR10577A (enExample)
DE (1) DE602007010010D1 (enExample)
DK (1) DK2066628T3 (enExample)
EC (1) ECSP099087A (enExample)
GT (1) GT200900016A (enExample)
IL (1) IL196587A0 (enExample)
MA (1) MA30643B1 (enExample)
MX (1) MX2009000830A (enExample)
NO (1) NO20090862L (enExample)
PE (1) PE20080549A1 (enExample)
PT (1) PT2066628E (enExample)
TN (1) TNSN08515A1 (enExample)
TW (1) TW200821286A (enExample)
WO (1) WO2008014186A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009072576A1 (ja) * 2007-12-04 2011-04-28 サッポロビール株式会社 骨形成促進剤
MX2011005120A (es) * 2008-11-17 2011-05-30 Hoffmann La Roche Acidos naftilaceticos.
SI2558447T1 (sl) 2010-03-22 2015-01-30 Actelion Pharmaceuticals Ltd. Derivati 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-karbazola in njihova uporaba kot modulatorji prostaglandinskega receptorja d2
EP2697223B1 (en) 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
US9797903B2 (en) 2012-10-24 2017-10-24 Winthrop-University Hospital Non-invasive biomarker to identify subject at risk of preterm delivery
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
HRP20181555T1 (hr) 2014-03-17 2018-11-30 Idorsia Pharmaceuticals Ltd Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2
EP3119780B1 (en) 2014-03-18 2018-08-29 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EA035752B1 (ru) 2015-09-15 2020-08-05 Идорсиа Фармасьютиклз Лтд КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-2-(8-((5-ХЛОРПИРИМИДИН-2-ИЛ)(МЕТИЛ)-АМИНО)-2-ФТОР-6,7,8,9-ТЕТРАГИДРО-5Н-ПИРИДО[3,2-b]ИНДОЛ-5-ИЛ)УКСУСНОЙ КИСЛОТЫ И СОДЕРЖАЩИЕ ЕЁ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
JP7455762B2 (ja) * 2018-05-09 2024-03-26 グルソックス・バイオテック・アーベー 選択的なNox阻害活性を有する新規のスルホンアミド誘導体
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN111333516B (zh) * 2020-04-14 2022-09-06 国药集团化学试剂有限公司 一种2-氯-5-溴硝基苯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.

Also Published As

Publication number Publication date
EP2066628A1 (en) 2009-06-10
KR20090039735A (ko) 2009-04-22
TNSN08515A1 (en) 2010-04-14
WO2008014186A1 (en) 2008-01-31
DE602007010010D1 (de) 2010-12-02
EP2066628B1 (en) 2010-10-20
PT2066628E (pt) 2010-12-31
IL196587A0 (en) 2009-11-18
CA2659055A1 (en) 2008-01-31
GT200900016A (es) 2010-10-13
AU2007276885A1 (en) 2008-01-31
TW200821286A (en) 2008-05-16
US20090176804A1 (en) 2009-07-09
AR062051A1 (es) 2008-08-10
BRPI0714554A2 (pt) 2013-05-07
MA30643B1 (fr) 2009-08-03
ATE485270T1 (de) 2010-11-15
DK2066628T3 (da) 2011-02-07
NO20090862L (no) 2009-02-24
ECSP099087A (es) 2009-02-27
JP2009544721A (ja) 2009-12-17
PE20080549A1 (es) 2008-06-20
CR10577A (es) 2009-03-20
CL2007002163A1 (es) 2008-02-08
MX2009000830A (es) 2009-02-03

Similar Documents

Publication Publication Date Title
CO6190511A2 (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
MX2008016423A (es) Arilamidas sustituidas con tetrazol.
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
IL188453A0 (en) Cyclic anilino-pyridinotriazines
AR077014A1 (es) Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
AR065810A1 (es) Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
ATE483707T1 (de) 2-cyclopropylthiazolderivate
ES2422557T3 (es) Compuestos y composiciones como moduladores de la ruta Hedgehog
TW200744588A (en) Pharmaceutical composition for external use
HRP20130614T1 (en) Novel pyrazole-substituted arylamides
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
TW200745056A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
AR065714A1 (es) Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida
NO20090779L (no) 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister
AR076362A1 (es) Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras.
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
MX2009008028A (es) Agentes antiparasitarios.
GEP20115309B (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihy-droxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-arboxylic acid ethylamide and formulations comprising these forms
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate

Legal Events

Date Code Title Description
FC Application refused